As differences in PD-L1 expression were exclusively observed on intratumoral macrophages and were not present in the periphery, additional biomarkers will be required to monitor therapy response to ICB, especially in the context of glioblastoma patients. This evidence concerns the gene CD274 and glioblastoma.